Minerva Neurosciences, Inc.
No SEC Form 4 filings for $NERV in the last 30 days.
Minerva Neurosciences (Nasdaq: NERV) reported Q2 2026 results and updates. Its confirmatory Phase 3 trial of roluperidone (MIN-101C19) for schizophrenia negative symptoms is ongoing, with topline efficacy expected in 2H 2027. R&D rose to $7.2M in Q2 2026 from $1.3M. GAAP net income was $17.5M, driven by a $27.6M non-cash warrant gain.
Minerva Neurosciences, Inc. (NERV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d22348dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board
Wall Street Zen upgraded Minerva Neurosciences (NASDAQ:NERV) from "sell" to "hold," although the consensus rating on MarketBeat remains "Reduce." The company reported a quarterly EPS of -$0.36, missing estimates, and institutional ownership stands at approximately 34.56%. The stock's current market cap is $169.62 million with a P/E ratio of -2.12.
Over the past 7 days, alphai's AI scored 2 news stories mentioning NERV (Minerva Neurosciences, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent NERV coverage spans financial news, technology and earnings.
The article reinforces the clinical execution timeline for roluperidone’s confirmatory Phase 3, a key catalyst for valuation and risk.
The filing reinforces the roluperidone negative-symptom schizophrenia development timeline (topline efficacy targeted for 2H 2027) while highlighting sharply higher R&D and liabilities tied to the C19 program and warrant-liability mark-to-market.
The upgrade to 'Hold' by Wall Street Zen, despite a 'Reduce' consensus, suggests cautious optimism but limited short-term trading action.
The news pertains to corporate governance and does not directly affect NERV's operations or valuation.
The announcement of up to $200 million in funding for Minerva Neurosciences' schizophrenia drug trial has positively influenced investor sentiment towards NERV, reflecting confidence in its pipeline and potential growth.
alphai scores every news story that mentions NERV with an AI model for sentiment and relevance, and aggregates insider trades from Minerva Neurosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Minerva Neurosciences (Nasdaq: NERV) reported Q2 2026 results and updates. Its confirmatory Phase 3 trial of roluperidone (MIN-101C19) for schizophrenia negative symptoms is ongoing, with topline efficacy expected in 2H 2027. R&D rose to $7.2M in Q2 2026 from $1.3M. GAAP net income was $17.5M, driven by a $27.6M non-cash warrant gain.
7 min readMinerva Neurosciences, Inc. (NERV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d22348dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board
7 min readWall Street Zen upgraded Minerva Neurosciences (NASDAQ:NERV) from "sell" to "hold," although the consensus rating on MarketBeat remains "Reduce." The company reported a quarterly EPS of -$0.36, missing estimates, and institutional ownership stands at approximately 34.56%. The stock's current market cap is $169.62 million with a P/E ratio of -2.12.
3 min readDr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
2 min readMinerva Neurosciences Inc ( NASDAQ:NERV ) shares are climbing Tuesday after the company announced up to $200 million in funding to support development of roluperidone for schizophrenia.
3 min readFDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia ...
3 min readBURLINGTON, Mass., May 13, 2025 ( GLOBE NEWSWIRE ) -- Minerva Neurosciences, Inc. ( Nasdaq: NERV ) , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first ...
3 min read
